Dr Prasad has been a member of drug discovery teams that discovered multiple drug candidates advanced to various stages of preclinical and clinical development, including Merck’s MK-4965. He was the lead crystallographer and core member of the team that discovered Alogliptin - A Syrrx and Takeda San Diego's DPP4 inhibitor being marketed under the brand name Nesina® to treat type 2 diabetes and the first drug to be discovered using structure-based design at Syrrx. He designed, built and implemented fragment-based crystallography drug discovery technology platforms at Syrrx, Merck and Metabasis. He has co-authored over 40 peer-reviewed research articles and holds 6 US and international patents. He serves on the editorial board of Current Protein and Peptide Science, Chemical Sciences Journal and Organic and Medicinal Chemistry International Journal. Dr. Prasad obtained his PhD from the Indian Institute of Science, Bangalore, India and post-doctoral training at the University of Minnesota Medical School and the Scripps Research Institute, La Jolla, California, where he was Assistant Professor.
Dr. Mehta is a partner with Netgain Financial, where he is responsible for investments and advising young, emerging, innovative micro-cap and small-cap biotech, medical devices, diagnostics, life sciences and medically related technology high growth companies. He has worked both on the buy-side and sell-side in the healthcare-biotech investment community for the last 12 years and has broad and deep relationships with the biotech investors and various market participants. Prior to Netgain, Dr. Mehta was responsible for all the healthcare investment decisions for the Gemini hedge fund. As an investment banker for Granite Financial Group, Dr. Mehta successfully raised capital for numerous public and private life science companies. Prior to his career in biotech investments, he worked at a number of public and private biotech companies, including Nanogen, Diversa, Imgenex & Aethlon Medical in a variety of roles including business development, marketing and R&D. During his academic career, he conducted research in neuropharmacology at The Scripps Institute. Dr. Mehta completed a postdoctoral fellowship at Duke University. He received his Ph.D. degree in Biochemistry from the Indian Institute of Science, Bangalore and M.Sc. in Microbiology from the University of Baroda, India.
Dr. Williams has over 25 years of small molecule drug discovery and development experience in fields that include oncology and neuroscience. She held positions of increasing responsibility in the Medicinal Chemistry Department at Merck in West Point, PA, including Director of Medicinal Chemistry. She has led multiple small molecule drug discovery programs, highlighted by discovery and development of Telcagepant, the first orally active GPCR receptor antagonist for the treatment of acute migraine that advanced to Phase III clinical trials. Dr. Williams obtained her PhD in Chemistry from Michigan State University and completed post-doctoral studies at Stanford University. She is co-inventor on 46 issued US patents and has co-authored over 45 peer reviewed research publications.